Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680781 · ClinicalTrials.gov registry record · NA
Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT03680781: Completed NA study, sponsored by Stanford University.
NCT03680781 is a NA study that has completed, run by Stanford University. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03680781, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.
Interventions
- DEVICE Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC
- DEVICE Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-04-13 |
| Est. Completion | 2024-12-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03680781
The ClinicalTrials.gov registry entry for NCT03680781 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC is the first listed.
NCT03680781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03680781 about?
NCT03680781 is a clinical study titled "Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study". This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.
What is the current status of trial NCT03680781?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2018-04-13. Estimated completion is 2024-12-02.
What interventions are being tested in trial NCT03680781?
The interventions under investigation include: Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC (DEVICE), Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC (DEVICE).
Who is sponsoring clinical trial NCT03680781?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.